Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study

An interesting article from Sørensen et al. about long term survival from childhood ALL (acute lymphoblastic leukemia). According to this article the long term results have improved decade after decade. Still there is space for improvements. Even if it is a small part of the whole ALL treatment protocol, it is worth having the lumbar punctures right the first time.

“Among ALL survivors, it was found that late mortality continued to decrease over treatment decades. This was highly attributable to a decrease in mortality from relapse.”

Read the publication from here: Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study Pediatr Blood Cancer. 2022;

Gitte V. Sørensen1,2 Federica Belmonte3 Friederike Erdmann4,5 Hanna Mogensen6 Vanna Albieri3 Anna S. Holmqvist7 Laura Madanat-Harjuoja8 Mats Talbäck6 Mats M. Heyman9 Nea Malila8 Maria Feychting6
Kjeld Schmiegelow10 Jeanette F. Winther2,4 Henrik Hasle1

1 Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
2 Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark
3 Unit of Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
4 Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark
5 Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg
University Mainz, Mainz, Germany
6 Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
7 Department of Clinical Sciences, Lund University, Pediatric Oncology and Hematology, Skåne University Hospital, Lund, Sweden
8 Finnish Cancer Registry, Helsinki, Finland
9 Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
10 Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark

 

FDA grants breakthrough device designation for Injeq IQ-Tip® smart needle

Injeq is happy to announce that Injeq IQ-Tip device with its indications for use meet the criteria and have been […]
Read more »

Breakthrough Device designation granted by FDA

Injeq IQ-Tip system has been granted the Breakthrough Device designation by FDA! The FDA’s Breakthrough Devices Program is designed to […]
Read more »

Injeq grows – new distributor in Hong Kong

Injeq visited Hong Kong in May and met with local hospital management there. The interest towards Injeq IQ-Tip® system convinced […]
Read more »

Large multicenter trial of pediatric hemato-oncology patients sponsored by Injeq

A clinical investigation conducted in all five Finnish university hospitals and sponsored by Injeq has begun in May. A peer-reviewed […]
Read more »

Two more weeks to go!

There are two weeks left in Injeq’s share issue. Read the promising news and invest: Funding: Injeq Oyj (invesdor.com)   […]
Read more »

Injeq IQ-Tip®: Benefits for healthcare and society

Post-dural puncturel headache after lumbar puncture is a difficult post-procedure complication caused by cerebrospinal fluid seeping through the lumbar puncture […]
Read more »